Mivazerol: Difference between revisions
CSV import |
CSV import |
||
| Line 25: | Line 25: | ||
{{stub}} | {{stub}} | ||
<gallery> | |||
File:Mivazerol.png|Mivazerol | |||
</gallery> | |||
Latest revision as of 05:20, 3 March 2025
Mivazerol is a drug that was developed for the treatment of ischemic heart disease. It is a selective alpha 2 adrenergic agonist.
Pharmacology[edit]
Mivazerol works by stimulating alpha 2 adrenergic receptors, which are found in the heart and blood vessels. This stimulation leads to a decrease in heart rate and blood pressure, which can be beneficial in the treatment of ischemic heart disease.
Clinical Trials[edit]
Mivazerol has been tested in several clinical trials. In one study, it was found to reduce the incidence of myocardial infarction (heart attack) in patients undergoing non-cardiac surgery. However, in another study, it did not show a significant benefit in reducing the risk of death or heart attack in patients with stable angina.
Side Effects[edit]
The most common side effects of mivazerol include dizziness, headache, and nausea. Less common side effects include bradycardia (slow heart rate), hypotension (low blood pressure), and dry mouth.
Development and Approval[edit]
Mivazerol was developed by Hoffmann-La Roche, a Swiss multinational healthcare company. However, it has not been approved for use by the Food and Drug Administration (FDA) in the United States.
